Rohto Pharmaceutical Co.,Ltd.
[Rohto Pharmaceutical] Completion of Subsidiary Acquisition of Thann Oryza | May 2026
Rohto Pharmaceutical completed the share acquisition of Thann Oryza and became its parent company on May 29, 2026. The impact on future earnings is under review, and additional information will be disclosed when available.
Key Figures
- Share acquisition completion date: 2026-05-29
- Future outlook: Under review
- Specific financial figures related to the subsidiary acquisition are unknown
AI要約
Performance Overview
Rohto Pharmaceutical completed the share acquisition of Thann Oryza Co., Ltd. on May 29, 2026, thereby realizing its subsidiary. This aims to expand its business portfolio and strengthen market competitiveness. The impact on consolidated performance is currently under review, and detailed figures and forecasts have not been announced.
Future Outlook
The impact of the share acquisition on future performance is currently undecided, but it will be promptly disclosed once additional information is obtained. Investors should recognize that the subsidiary acquisition is part of the company's strategic initiatives and pay attention to future earnings trends.
Rohto Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
